Proton Therapy Indications for Cancer Treatment

Proton therapy is an advanced form of radiation therapy that may be considered for selected cancer patients, especially when tumors are located near sensitive organs or when reducing radiation exposure to healthy tissue is important. Eligibility depends on the cancer type, tumor location, stage, previous treatments, and evaluation by an oncology team.

What Cancers May Be Considered for Proton Therapy?

Proton therapy may be considered for a range of cancers where precise radiation delivery is important. It is often discussed for tumors near the brain, eyes, spinal cord, heart, lungs, liver, bladder, rectum, or developing tissues in children. Not every patient is suitable for proton therapy, and each case requires individualized medical review.

  • Head and neck cancers
  • Brain tumors
  • Breast cancer
  • Prostate cancer
  • Liver cancer
  • Lung cancer
  • Pediatric tumors
  • Bone and soft tissue sarcomas

Who May Benefit From Proton Therapy?

Patients who may benefit from proton therapy often include those with tumors close to sensitive structures, children whose healthy tissues are still developing, or patients whose treatment plan requires careful dose reduction to nearby organs. The potential benefit depends on the diagnosis, anatomy, treatment goals, and comparison with other radiation options.

How Is Eligibility for Proton Therapy Evaluated?

Eligibility is usually evaluated through medical records, imaging studies, pathology reports, and previous treatment history. The oncology team may compare proton therapy with other treatment options to determine whether proton therapy offers a meaningful clinical advantage for the individual patient.

Proton Therapy for International Patients

International patients may submit medical records for preliminary review before traveling to Guangzhou. This helps the medical team understand the diagnosis, previous treatment, and whether proton therapy evaluation may be appropriate. Patients can then receive guidance on appointment scheduling, required documents, and next steps.

Frequently Asked Questions About Proton Therapy Indications

What cancers can be treated with proton therapy?

Proton therapy may be considered for selected cancers such as head and neck cancers, brain tumors, breast cancer, prostate cancer, liver cancer, lung cancer, pediatric tumors, and sarcomas. Suitability depends on individual evaluation.

Is proton therapy suitable for all cancer patients?

No. Proton therapy is not suitable for every patient. The decision depends on cancer type, tumor location, stage, previous treatments, and whether proton therapy offers an advantage over other treatment options.

Why is proton therapy often discussed for tumors near sensitive organs?

Proton therapy can deliver radiation with a distinct dose distribution that may help reduce unnecessary radiation exposure beyond the tumor area, which can be important when tumors are near sensitive organs.

Can children receive proton therapy?

For selected pediatric tumors, proton therapy may be considered because reducing radiation exposure to developing healthy tissues can be important. Each pediatric case requires careful specialist evaluation.

Can international patients request a review before traveling?

Yes. International patients can submit medical records, imaging, and pathology information for preliminary review before making travel arrangements.

Head & Neck Cancer

27% risk reduction of a feeding tube for oropharyngeal cancer

Fewer side effects for the first 3-month post treatment,quicker return to normal life with oropharyngeal cancer

45% reduction in overall risk of a feeding tube for nasopharyngeal cancer

Dramatic reduction of negative impact on taste, nausea, and painful changes to the mouth in salivary gland treatment

44% relative increase of 5-year survival rate for nasal and paranasal sinus cavity cancers

Esophageal Cancer

10% increase of 5-year overall survival rate for stage I-III

10% increase of 5-year overall survival rate of local cancer control for stage II-III

15% decrease of distant metastasis of 5-year overall survival rate for stage II-III

26% reduction in pulmonary toxicity compared to X-ray therapy (IMRT)

21% risk reduction in the risk of severe, treatment related lymphopenia, particularly in lower esophagus

3-4-day reduction in average hospital stay after surgery

Breast Cancer

88% less radiation dose to the heart for left sided breast cancer

44% reduction in clinically significant radiation doses to theu lng

90% of partial breast irradiation cases result in good to excleelnt cosmetic outcomes for 5 years

Well tolerated – Less than 4% serious side effects (grade 3) in locally advanced breast cancer

Liver cancer

35% relative increase of 5-year overall survival rate for stage II-III

56% relative reduction in incidences of serious (grade 3) pain with swallowing (esophagitis)

Up to 4-week reduction in treatment time for select cases

Other Advantages

26–39% risk reduction in secondary malignancies

Overall/All Cancers

31% relative reduction in occurrence of secondary cancers after treatment

Sinonasal/Nasal Cavity Cancer

38% relative improvement of 5-year overall survival rate

Nasopharyngeal Cancer

60% reduction in the need for nasogastric tube feeding

Oropharyngeal Cancer

50% reduction in the need for nasogastric tube feeding 74% relative reduction in moderate to severe xerostomia(dry mouth)

Lung Cancer

35% relative increase of 5-year overall survival rate for stage II-III

56% relative reduction in serious (grade 3) pain with swallowing (esophagitis)

Up to 4-week reduction in treatment time for selected cases

Rectal/Anal Cancer

3More than 50% reduction in radiation dose to critical structures including bone marrow

Chordoma

49–56% relative improvement of tumor control rate

153% relative improvement of 5-year overall survival rate

Sarcoma

20% improvement of local tumor control rate

Pediatric Tumors

Reduced impact on height and IQ

Lower risk of secondary tumors

Prostate Cancer

5% higher of 5-year overall survival rate in intermediate risk

Patients receiving proton therapy report the highest quality of life compared to surgery, x-ray, or brachytherapy

35% less radiation to bladder and 59% less radiation to rectum

42% risk reduction in secondary malignancy

50% reduction in treatment related bowel frequency and urgency at 2 years

21% lower of risk in urinary toxicity for 2 years

25% lower of risk in erective dysfunction for 2 years